{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:33:36Z","timestamp":1781123616427,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03051-0","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:53:59Z","timestamp":1733727239000},"page":"849-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry"],"prefix":"10.1007","volume":"42","author":[{"given":"Njira L.","family":"Lugogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Gon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9anne","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"de Prado G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"3051_CR1","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/07\/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. Accessed July 27, 2023."},{"key":"3051_CR2","unstructured":"World Health Organization. Asthma. 2023. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma. Accessed July 27, 2023."},{"key":"3051_CR3","unstructured":"US Centers for Disease Control. Uncontrolled Asthma Among Adults. 2019. Available at: https:\/\/www.cdc.gov\/asthma\/asthma_stats\/uncontrolled-asthma-adults-2019.htm. Accessed July 27, 2023."},{"key":"3051_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12948-021-00146-9","volume":"19","author":"GW Canonica","year":"2021","unstructured":"Canonica GW, Blasi F, Crimi N, et al. Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. Clin Mol Allergy. 2021;19:5.","journal-title":"Clin Mol Allergy"},{"key":"3051_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1055\/s-0032-1326962","volume":"33","author":"ID Pavord","year":"2012","unstructured":"Pavord ID. Asthma phenotypes. Semin Respir Crit Care Med. 2012;33:645\u201352.","journal-title":"Semin Respir Crit Care Med"},{"key":"3051_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma\u2013present in most, absent in many. Nat Rev Immunol. 2015;15:57\u201365.","journal-title":"Nat Rev Immunol"},{"key":"3051_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","volume":"12","author":"D Chodankar","year":"2021","unstructured":"Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12:171\u20134.","journal-title":"Perspect Clin Res"},{"key":"3051_CR8","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111:5147\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR9","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111:5153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"key":"3051_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floch","year":"2020","unstructured":"Le Floch A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188\u2013204.","journal-title":"Allergy"},{"key":"3051_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344.","journal-title":"Lancet"},{"key":"3051_CR13","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"3051_CR14","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Parameswaran N, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med"},{"key":"3051_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10:11\u201325.","journal-title":"Lancet Respir Med"},{"key":"3051_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s12325-022-02399-5","volume":"40","author":"R Gall","year":"2023","unstructured":"Gall R, Jain N, Soong W, et al. Dupilumab-treated patients with asthma in the real world: the RAPID global registry. Adv Ther. 2023;40:1292\u20138.","journal-title":"Adv Ther"},{"key":"3051_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK, Taylor DR, Bateman ED, et al. An Official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59\u201399.","journal-title":"Am J Respir Crit Care Med"},{"key":"3051_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902\u20137.","journal-title":"Eur Respir J"},{"key":"3051_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","volume":"99","author":"EF Juniper","year":"2005","unstructured":"Juniper EF, Svensson K, M\u00f6rk A-C, St\u00e5hl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553\u20138.","journal-title":"Respir Med"},{"key":"3051_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14:32\u20138.","journal-title":"Eur Respir J"},{"key":"3051_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ahg.12506","volume":"87","author":"J Liu","year":"2023","unstructured":"Liu J, Xu H, Cupples LA, O'Connor GT, Liu C-T. The impact of obesity on lung function measurements and respiratory disease: a Mendelian randomization study [abstract]. Ann Hum Genet. 2023;87:174\u201383.","journal-title":"Ann Hum Genet"},{"key":"3051_CR22","unstructured":"World Health Organization. Obesity. 2021. Available at: https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/6-facts-on-obesity. Accessed July 27, 2023."},{"key":"3051_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.18176\/jiaci.0316","volume":"29","author":"F Garcia-Rio","year":"2019","unstructured":"Garcia-Rio F, Alvarez-Puebla MJ, Esteban-Gorgojo I, Barranco P, Olaguibel JM. Obesity and asthma: key clinical questions. J Investig Allergol Clin Immunol. 2019;29:262\u201371.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"3051_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaci.2020.08.011","volume":"146","author":"S Miethe","year":"2020","unstructured":"Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146:685\u201393.","journal-title":"J Allergy Clin Immunol"},{"key":"3051_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40001-023-01089-4","volume":"28","author":"X Han","year":"2023","unstructured":"Han X, He X, Hao G, Cao L, Qi Y, Han K. The association of asthma duration with body mass index and weight-adjusted-waist index in a nationwide study of the U.S. adults. Eur J Med Res. 2023;28:122.","journal-title":"Eur J Med Res."},{"key":"3051_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40272-022-00554-7","volume":"25","author":"SC Guerrero","year":"2023","unstructured":"Guerrero SC, Panettieri RA Jr, Rastogi D. Mechanistic links between obesity and airway pathobiology inform therapies for obesity-related asthma. Paediatr Drugs. 2023;25:283\u201399.","journal-title":"Paediatr Drugs"},{"key":"3051_CR27","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.3390\/ijms24076807","volume":"24","author":"A Alterki","year":"2023","unstructured":"Alterki A, Abu-Farha M, Al Shawaf E, Al-Mulla F, Abubaker J. Investigating the relationship between obstructive sleep apnoea, inflammation and cardio-metabolic diseases. Int J Mol Sci. 2023;24:6807.","journal-title":"Int J Mol Sci"},{"key":"3051_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40001-023-01097-4","volume":"28","author":"D Wang","year":"2023","unstructured":"Wang D, Zhou Y, Chen R, et al. The relationship between obstructive sleep apnea and asthma severity and vice versa: a systematic review and meta-analysis. Eur J Med Res. 2023;28:139.","journal-title":"Eur J Med Res"},{"key":"3051_CR29","unstructured":"DUPIXENT\u00ae (dupilumab). Highlights of Prescribing Information. US Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s044lbl.pdf. Accessed 27 July 2023."},{"key":"3051_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.969243","volume":"9","author":"G Guida","year":"2022","unstructured":"Guida G, Bagnasco D, Carriero V, et al. Critical evaluation of asthma biomarkers in clinical practice. Front Med (Lausanne). 2022;9:969243.","journal-title":"Front Med (Lausanne)"},{"key":"3051_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1183\/13993003.00850-2016","volume":"48","author":"M Tommola","year":"2016","unstructured":"Tommola M, Ilmarinen P, Tuomisto LE, et al. The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J. 2016;48:1298\u2013306.","journal-title":"Eur Respir J"},{"key":"3051_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000377","volume":"6","author":"JJK Jaakkola","year":"2019","unstructured":"Jaakkola JJK, Hernberg S, Lajunen TK, Sripaijboonkij P, Malmberg LP, Jaakkola MS. Smoking and lung function among adults with newly onset asthma. BMJ Open Respir Res. 2019;6:e000377.","journal-title":"BMJ Open Respir Res"},{"key":"3051_CR33","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.jaip.2022.04.034","volume":"10","author":"NC Thomson","year":"2022","unstructured":"Thomson NC, Polosa R, Sin DD. Cigarette smoking and asthma. J Allergy Clin Immunol Pract. 2022;10:2783\u201397.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3051_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41533-022-00309-4","volume":"32","author":"J Takala","year":"2022","unstructured":"Takala J, V\u00e4h\u00e4talo I, Tuomisto LE, Niemel\u00e4 O, Ilmarinen P, Kankaanranta H. Documentation of smoking in scheduled asthma contacts in primary health care: a 12-year follow-up study. NPJ Prim Care Respir Med. 2022;32:44.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3051_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cea.14112","volume":"52","author":"D Charles","year":"2022","unstructured":"Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022;52:616\u201327.","journal-title":"Clin Exp Allergy"},{"key":"3051_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","volume":"132","author":"G Scelo","year":"2024","unstructured":"Scelo G, Torres-Duque CA, Maspero J, et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024;132:42\u201353.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3051_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","volume":"209","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Scelo G, Larenas-Linnemann DES, et al. Association between T2-related comorbidities and effectiveness of biologics in severe asthma. Am J Respir Crit Care Med. 2024;209:262\u201372.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03051-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:52:36Z","timestamp":1738407156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03051-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3051"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03051-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Njira L. Lugogo reports consulting fees from Amgen, AstraZeneca, Avillion, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva; honoraria for non-speakers bureau presentations from AstraZeneca and GSK; and travel support from AstraZeneca. Her institution received research support from Amgen, AstraZeneca, Avillion, Evidera, Gossamer Bio, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva. She is an honorary faculty member of the Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role. Xavier Soler, Changming Xia, Amr Radwan, and Yamo Deniz are Regeneron Pharmaceuticals Inc. employees and shareholders. Yasuhiro Gon reports research, speaker fees, and consultancy fees from AstraZeneca, GSK, Kyorin Pharmaceutical, Novartis, and Sanofi. Andr\u00e9anne Cot\u00e9 is\u00a0a member of the advisory boards for AstraZeneca, GSK, Sanofi, and Valeo; has received speaker fees from AstraZeneca, GSK, and Sanofi; and has received research support from GSK and AstraZeneca. Ole Hilberg is member of Sanofi advisory boards. Yi Zhang is a former Regeneron Pharmaceuticals Inc. employee and shareholder. Luc\u00eda de Prado G\u00f3mez, Paul J. Rowe, and Juby A. Jacob-Nara are Sanofi employees and may hold stock and\/or stock options in the company. Anju T. Peters has received research and consulting support from AstraZeneca, GSK, Merck, Optinose, Regeneron Pharmaceuticals Inc., and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"RAPID is being conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. The RAPID protocol was reviewed and approved by the respective institutional review boards before patient recruitment. All patients provided written informed consent. For patients under the age of 18\u00a0years, both parental\/legal guardian consent and patient assent were required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}